Eurand N.V. (EURX) Completes Study on Zentase
More News related to EURX
- Oppenheimer Initiates Coverage on Eurand (EURX)
- FDA Advises Eurand (EURX) That It Has Extended the Review Period for ZENPEP(TM) Therapy
- FDA Extends Review Period for Eurand's ZENPEP(TM) Pancreatic Enzyme Replacement Therapy
- Eurand to Present at UBS Global Specialty Pharmaceuticals Conference in London
- Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
More News related to Corporate News
- Argon ST (STST) Awarded $8.3 Million to Provide U.S. Army Technology Enabler Development
- McKesson (MCK) Renews Pharmaceutical Distribution Agreement with CVS Caremark (CVS)
- Oclaro (OCLR) Closes Deal with Newport (NEWP) to Exchange Strategic Assets
- Cardinal Health (CAH) Renews Distribution Agreement with CVS Caremark (CVS) Through Mid-2013
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
Eurand N.V. (Nasdaq: EURX) today announced the completion of a gastrointestinal bioavailability study on Zentase(tm), Eurand's lead product candidate for the treatment of exocrine pancreatic insufficiency (EPI). The study was conducted in chronic pancreatitis patients in the U.S.
Eurand N.V., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
